3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Pemetrexed
5
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cisplatin
4
fludarabine
3
Cyclophosphamide
3
Radiotherapy, Intensity-Modulated
2
Cerebral Decortication
2
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
avelumab
1
atezolizumab
1
Platinum
1
Influenza Vaccines
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Blood Component Removal
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
Erlotinib Hydrochloride
×
90 days
×
Clear all
No trials found.